Lead Product(s): RKP00156
Therapeutic Area: Oncology
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: ASKA Pharmaceutical Co.
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement January 14, 2020
Under the agreement, ASKA will obtain a right to exercise an option to jointly develop with KinoPharma and to exclusively sell the drug in Japan.